The biopharmaceutical company “Biopharma” is building a plant in Romania, according to the company’s president, Konstantin Efimenko.
“We are already building a plant in Romania,” he said at the “Industrial Evolution: Manufacturing Drives the Economy” forum in Bila Tserkva (Kyiv Oblast) on Thursday, without specifying the project’s timeline.
Commenting on Ukraine’s investment appeal, Yefimenko noted that “no foreign companies will come here if things aren’t good for our own people.”
He also emphasized the importance of developing the education sector. “We need to keep the National Math Test in schools, but why aren’t we talking about the fact that math education in schools is weak, that children graduate from school knowing nothing? We have two ‘happiness’ classes a week, and chemistry just once every two weeks. What kind of technologies will we be able to develop?” he said, pointing out the outdated state of university facilities.
“Tear them down and forget about them—they can’t be renovated. We need to start from scratch,” he said.
Yefimenko reported that “Biofarma” plans to invest $25 million “in another laboratory,” without providing further details.
He also reported that “Biofarma” has registered its albumin product in Brazil.
“We need to create conditions so that no prosecutors come to us—only the tax inspectorate should visit us. Tell me, what difference does it make to the state how I registered my albumin in Brazil? I’m number one in Brazil right now. The Brazilians are happy, I’m happy. Anything that’s good for Biofarma is good for Ukraine, and for Bila Tserkva, at the very least. Why do you need to regulate what I’m doing in Brazil?” he said.
As previously reported, in 2024, Biofarma announced plans to build a plant in Romania.
“Biofarma” exports its products to dozens of countries and plans to expand its presence in Europe, the Middle East, and Latin America, while also continuing to increase its production capacity.
